BioXcel Corporation reports the initiation of a strategic big data collaboration with Pronutria Biosciences to identify diseases characterized by high unmet need for therapies and nutritional products that are amenable to Pronutria’s novel technology platform.

Pronutria is a biotechnology company pioneering a new class of products to mediate amino acid biology. Through this partnership, Pronutria will utilize BioXcel’s first-in-class Big Data Innovation Lab (BDI-Lab) to develop biologics that leverage its novel platform and amino acid-based approach.

“With a proprietary platform of over 1 billion protein and fragment sequences to identify disease specific product candidates, we are unlocking the regenerative potential of homeostatic amino acid biology to transform the lives of patients and their families,” said Dr. Peter Mueller, President of R&D and Chief Scientific Officer at Pronutria.